Huntington National Bank Sells 26,219 Shares of Edwards Lifesciences Co. (NYSE:EW)

Huntington National Bank reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 11.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 194,928 shares of the medical research company's stock after selling 26,219 shares during the period. Huntington National Bank's holdings in Edwards Lifesciences were worth $14,431,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. raised its holdings in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after acquiring an additional 273 shares during the last quarter. Nordea Investment Management AB grew its position in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its stake in Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock valued at $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $3,702,000. Finally, Avanza Fonder AB acquired a new stake in Edwards Lifesciences in the 4th quarter worth about $4,845,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Remove Ads

Analysts Set New Price Targets

EW has been the topic of several research analyst reports. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Piper Sandler raised their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and upped their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday, February 13th. Finally, Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $79.95.

Insider Buying and Selling

In related news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the sale, the chief financial officer now directly owns 30,387 shares of the company's stock, valued at $2,153,526.69. This represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,553 shares of company stock valued at $4,513,064 over the last three months. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $0.65 on Tuesday, hitting $69.65. The company's stock had a trading volume of 1,030,006 shares, compared to its average volume of 4,835,174. The company has a market capitalization of $40.94 billion, a price-to-earnings ratio of 10.00, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The stock's 50-day moving average is $71.74 and its two-hundred day moving average is $70.67.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.